Form 4: PTC Therapeutics Director Sells Shares Under 10b5-1 Plan

PTC Therapeutics Director Emma Reeve executed a planned sale of common stock and exercised options on October 30, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Director Emma Reeve engaged in multiple transactions involving PTC Therapeutics common stock and stock options on October 30, 2025.
• Reeve sold a total of 15,666 shares of common stock at a price of $69.5 per share.
• Concurrently, Reeve acquired 12,000 shares of common stock by exercising stock options at an exercise price of $38.1 per share.
• All transactions were conducted pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 4, 2025.
• Following these transactions, Emma Reeve beneficially owns 6,666 shares of common stock directly.
• The 12,000 stock options exercised were previously exercisable and had an expiration date of January 6, 2032.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a pre-scheduled insider transaction under a 10b5-1 plan, which is a routine disclosure and not indicative of new company performance or strategic shifts.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating a scheduled, non-discretionary sale rather than a reaction to recent events.
• The exercise of options at $38.1 and subsequent sale at $69.5 indicates a significant profit for the director on the exercised shares.

Negatives

• The director's direct beneficial ownership of common stock decreased by 3,666 shares (15,666 sold 12,000 acquired) following these transactions, which could be interpreted as a reduction in insider exposure.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends, focusing solely on the individual's trading activity.

Related Party Transactions

• The filing itself details a related party transaction, specifically the sale and acquisition of company securities by a director, Emma Reeve.

Stakeholder Impact

• Shareholders may interpret the net reduction in the director's common stock holdings as a signal, although the 10b5-1 plan context suggests it was pre-planned and not based on recent material non-public information.

Key Dates

Keywords

PTC Therapeutics, PTCT, Insider Trading, Form 4, Stock Options, Director, 10b5-1 Plan, Common Stock